CLINICAL TRIAL: SUBJECTS ON POTENT ANTIRETROVIRAL THERAPY WITH PLASMA HIV-1 RNA

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 A5212是一项双盲、II期研究，旨在评价帕利弗明（重组人角质形成细胞生长因子[rHuKGF]）是否可通过增强病毒载量受抑制但CD 4 + T细胞计数不足的HIV-1感染受试者的胸腺生成有效增加CD 4+淋巴细胞计数。 入组时，受试者将被随机分配至4个治疗组之一，接受安慰剂或3种剂量水平的帕利佛明静脉推注（IV）每日一次，持续3天。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5212 is a double blind, phase II study designed to evaluate whether palifermin (recombinant human keratinocyte growth factor [rHuKGF]) is effective at increasing CD4+ lymphocyte counts through enhanced thymopoiesis in HIV-1-infected subjects with suppressed viral loads but inadequate CD4+ T cell counts. At entry, subjects will be randomized to one of four treatment arms to receive either placebo or one of three dose levels of palifermin intravenously (IV) bolus daily for 3 days.